💊 의약품 A-Z 🧬 표적 🛠 도구 📚 가이드
전체 의약품 약물 분류 치료 영역 부작용
가이드 용어집 연대표
비교 약물 체내 여정 약물 계열
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Midazolam

CHEMBL655 Phase 4 승인됨 Small molecule
Half-Life
1.5-2.5 hours
Bioavailability
—
Protein Binding
—
Molecular Weight
325.8 g/mol
LogP
2.5
Phase
4

This short-acting benzodiazepine medication produces sedation, reduces anxiety, and causes temporary memory loss, making it useful for procedural sedation and anesthesia. It acts quickly and wears off relatively fast compared to other medications in its class.

분자량

325.7670 g/mol

LogP

2.50

TPSA

30.20 Ų

리핀스키 5의 법칙

통과

치료 영역

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Glaucoma Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Oncology Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Stroke Obesity Lymphoma Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis Gout Chronic Pain Hepatitis C Tuberculosis Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

약물 분류

N — N - Nervous System

작용 기전

Ultra-short-acting benzodiazepine GABA-A receptor positive allosteric modulator.

Pharmacokinetics (PK)

Half-Life 1.5-2.5 hours

Pharmacodynamics (PD)

기전

Ultra-short-acting benzodiazepine GABA-A receptor positive allosteric modulator.

2D 구조

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
Cc1ncc2n1-c1ccc(Cl)cc1C(c1ccccc1F)=NC2

                

                

                
                

                    
InChI

                    
InChI=1S/C18H13ClFN3/c1-11-21-9-13-10-22-18(14-4-2-3-5-16(14)20)15-8-12(19)6-7-17(15)23(11)13/h2-9H,10H2,1H3

                

                

                

                    
                    

                        
Molecular Formula

                        
C18H13ClFN3

                    

                    
                    

                        
HBD / HBA

                        
- / 3

                    

                    
                    

                        
회전 가능 결합

                        
1

                    

                    
                    
                    

                        
무거운 원자

                        
23

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
자주 묻는 질문

                

                    
                    

                        
                        

                            
This short-acting benzodiazepine medication produces sedation, reduces anxiety, and causes temporary memory loss, making it useful for procedural sedation and anesthesia. It acts quickly and wears off relatively fast compared to other medications in its class.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Ultra-short-acting benzodiazepine GABA-A receptor positive allosteric modulator.

                        

                    

                    

                    
                    

                        
                        

                            
Key pharmacokinetic parameters for Midazolam: Half-life: 1.5-2.5 hours.

                        

                    

                    

                    

                        
                        

                            
Yes, Midazolam is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            
            

                
Related Drugs


                
                

                    
Same Drug Class

                    

                        
                        
                            Acetaminophen
                            Small molecule
                        
                        
                        
                            Aspirin
                            Small molecule
                        
                        
                        
                            Sertraline
                            Small molecule
                        
                        
                        
                            Escitalopram
                            Small molecule
                        
                        
                    

                

                

                
            

            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL655.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 4192.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.




        


        
        
    


    



    
의학적 면책조항

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.